Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 9/20 | 0.42 |
| ▸ | CA12 | O43570 | 7/20 | 0.42 |
| ▸ | CA1 | P00915 | 7/20 | 0.42 |
| ▸ | CA2 | P00918 | 7/20 | 0.42 |
| ▸ | CA9 | Q16790 | 7/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134575 | 0.93 | TP53 (0.43) | TP53MAPTCA12CA1CA2 | |
| SCHEMBL6133896 | 0.91 | TP53 (0.42) | TP53MAPTCA12CA1CA2 | |
| SCHEMBL6135226 | 0.91 | MAPT (0.43) | TP53MAPTCA12CA1CA2 | |
| SCHEMBL6132169 | 0.88 | MAPT (0.43) | TP53MAPTCA12CA1CA2 | |
| SCHEMBL6132626 | 0.86 | TP53 (0.46) | TP53MAPTCA12CA1CA2 | |
| SCHEMBL6134595 | 0.85 | CA12 (0.42) | TP53MAPTCA12CA1CA2 | |
| SCHEMBL6134951 | 0.85 | CA12 (0.52) | TP53MAPTCA12CA1CA2 | |
| SCHEMBL6132918 | 0.85 | MAPT (0.40) | TP53MAPTCA12CA1CA2 | |
| SCHEMBL6134753 | 0.85 | MAPT (0.39) | TP53MAPTCA12CA1CA2 | |
| SCHEMBL6135143 | 0.84 | MAPT (0.42) | TP53MAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261177-A1 | Compound | ASTELLAS PHARMA INC. (JP) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261177-A1 | Compound | MANBA, MAN2B1, MAN2A1 | TP53 3972/4885MAPT 1629/4885CA12 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.